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Available online xxxxIntroduction: Research suggests that people with schizophrenia have autonomic dysfunctions. These have been
linked to functioning problems, symptoms and considered a risk factor for illness chronicity. The aim of this
study is to introduce a newMobile Health (mHealth)method using wearable technology to assessing autonomic
activity in people's everyday life. We aim to evaluate the newmethod acceptability and characterise the associ-
ation between schizophrenia illness features and autonomic abnormalities.
Method: Thirty participants with schizophrenia and 25 controls were asked to wear a mHealth devicemeasuring
autonomic activity andmovements during their normal everyday life. Measures of device use acceptability were
collected from all participants. Participants with schizophrenia were also assessed for symptoms and functioning
levels. Measures of heart rate variability (HRV), electrodermal activity (EDA) and movement were collected by
the device and groups were compared. Correlation between physiological measures, functioning, symptoms
and medication levels were assessed in people with schizophrenia.
Results: The mHealth device method proved to be acceptable and produced reliable measures of autonomic ac-
tivity and behaviour. Compared to controls, people with schizophrenia showed lower levels of HRV, movement
and functioning. In people with schizophrenia illness severity, particularly positive symptoms, was associated
with parasympathetic deregulation.
Conclusions: Autonomic abnormalities can be detected using wearable technology from people's everyday life.
These are in line with previous research and support the notion that autonomic deregulation are relevant illness
features for mental and physical health in schizophrenia. Thismethodmay be developed as amonitoring system
for well-being and relapse prevention.
© 2017 Elsevier B.V. All rights reserved.Keywords:
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Mobile health
Digital technology1. Introduction
Peoplewith schizophrenia experience a significant reduction in their
functioning levels from illness onset (Cella et al., 2016; Reichenberg et
al., 2014). Functioning problems are largely responsible for the long
term consequences of the illness, poor life quality and much of the ill-
ness associated burden for sufferers, carers, the health care system
and the society (Harvey, 2009; Jaaskelainen et al., 2013; Stouten et al.,
2014). Much of the work done in this area has used interview based
tools to assess the illness impact on social and occupational levels
(Cella et al., 2016; Heinrichs et al., 2006; Schneider and Struening,
1983).
Challenges in the definition of functioning and its broad conceptual-
isation have made it difficult to study the biological markers associatedlogy, Institute of Psychiatry,
espigny Park, SE5 8AF London,
sing wearable technology to
16/j.schres.2017.09.028with this illness feature. One exception is research in the field of auto-
nomic nervous system activity. Since the 80s autonomic system dys-
function have been consistently linked to functioning difficulties in
people with schizophrenia (Brekke et al., 1997; Ohman et al., 1989;
Tarrier and Barrowclough, 1990). Despite not always converging in
identifying a specific biological system, the majority of the evidence
supports the notion that autonomic deregulation may be implicated in
functioning problems (Fujibayashi et al., 2009). Several studies suggest
that reduce vagal tone and heart rate variability (HRV) are found in peo-
ple with schizophrenia, and to a lesser degree in unaffected relatives
(e.g. Bar et al., 2005; Ieda et al., 2014; Moon et al., 2013) and this is as-
sociated with lower scores on the Global Assessment of Functioning
(Khandoker et al., 2010), illness chronicity (Toichi et al., 1999) and
both positive and negative symptoms severity (Boettger et al., 2006;
Kim et al., 2004). A recent meta-analysis suggested that this feature
should be considered an endophenotype of schizophrenia (Clamor et
al., 2016). Less convergent are findings from studies investigating sym-
pathetic regulation. Some studies found people with schizophrenia
displaying elevated event related phasic and tonic electrodermaldetect the autonomic signature of illness severity in schizophrenia,
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studies found no differences (Castro et al., 2008; Hempel et al.,
2005). Recently Montaquila et al. (2015) proposed that sympathetic
deregulation in people with schizophrenia may be dependent on di-
minished parasympathetic activity and the consequent difficulties of
the parasympathetic system to down-regulate sympathetic activity.
This account may explain the incongruent sympathetic activation
findings and explain why event-related activation is largely found
in the normal range while there may be a selective difficulty in
down-modulating this response. To date only a limited number of
studies measured sympathetic and parasympathetic activity simul-
taneously and therefore this hypothesis has only partial empirical
support.
Most of the studies available in the literature assess the relation-
ship between autonomic activity and schizophrenia illness features
using laboratory based paradigms. This method however does not
allow assessing directly the relevance of autonomic events to func-
tioning problems. Recent technological developments produced de-
vices capable of recording autonomic activity from wearable
devices. These are worn on such as regular cloths or watches and
allow regular information gathering over extended time periods.
This new prospect has made physiological research outside the labo-
ratory accessible and allowed, for the first time, to study how auto-
nomic deregulations contribute to mental health symptoms
(Okruszek et al., 2016). This methodology is also beginning to be
used for monitoring and prevention in neurological and cardiometa-
bolic conditions (Corino et al., 2017; Picard et al., 2017; Sarkis et al.,
2015).
The use ofwearables andmobile health (mHealth) devices in people
with schizophrenia may also be useful to support intervention to im-
prove cardiometabolic health (Mitchell and De Hert, 2015). Recent re-
search suggested that wearable devices may be useful to support
weight loss and improve lifestyle in people with severe mental health
condition (Naslund et al., 2016; Naslund et al., 2017).
This study has three aims. The first is to evaluate the acceptability
and feasibility of the new mHealth technology in people with schizo-
phrenia. The second is to compare sympathetic andparasympathetic ac-
tivity between people with schizophrenia and healthy controls during
everyday life. The third is to assess the association of possible autonomic
abnormalities with functional difficulties and symptoms of
schizophrenia.2. Methods
2.1. Design
Cross-sectional comparing a group of people with schizophrenia
with a control group.2.2. Participants
Participants with schizophrenia were recruited from the National
Health System, Community Mental Health Teams in South London
(UK). Inclusion criteria were: (i) DSM-IV diagnosis of schizophrenia,
(ii) aged 18–65, (iii) good command of English language. Exclusion
criteria: (i) recent medication change (i.e. in the last month), (ii) poor
literacy or learning disability, (iii) a DSM-IV diagnosis of substance de-
pendence. Participants in the control groupwere healthy individuals re-
cruited with advertisement from the local community to match the
clinical group for age and gender. Inclusion criteria were set to allow ap-
propriate group matching: age between 18 and 65 years, no history of
DSM-IV diagnosis of schizophrenia or other mental disorder, no evi-
dence of head injury/organic brain disorder, no learning disability and
no diagnosis of substance dependence.Please cite this article as: Cella, M., et al., Using wearable technology to
Schizophr. Res. (2017), https://doi.org/10.1016/j.schres.2017.09.0282.3. Measures
For all participants we collected demographic information (e.g. age,
gender). For participants in the clinical group we collected information
on their mental health history and current medication. Antipsychotic
dosage was converted to chlorpromazine equivalents using guidelines
formWoods (Woods, 2003).
2.4. Acceptability
The assessment acceptability was evaluated using an acceptability
feedback questionnaire. The assessment questions were designed to
be rated using a 7-point Likert scale. Questions enquired whether: i)
the device disrupted participants' life; ii) stopped participants from
doing usual activities; iii) it was embarrassing to wear the device
around other people; iv) it was easy to remember to wear the device;
v) it was enjoyable wearing the device as part of this study. This mea-
sure was used in a previous study involving people with schizophrenia
and a similar mHealth device (Edwards et al., 2016).
2.5. Functioning
Functioning was assessed with the time use survey (Short, 2006).
This is a semi-structured interview asking participants to retrospective-
ly report the time spent in a variety of activities in the last month (e.g.
work, education, socializing, sleep). Time spent in each activity is con-
verted in number of hours per week. Time spent in structured activity
is considered and index of function levels. Structured time includes ac-
tivities such as work, volunteering, studying, socializing, travelling,
hobbies, house chores, caring for others and looking after children.
This measure was used in previous research with people with schizo-
phrenia (Cella et al., 2016).
2.6. Symptoms
Symptom severity was measured using the Positive and Negative
Syndrome Scale (PANSS) (Kay et al., 1987). This is a 30-item assessing
symptom severity in the past week. For this study we considered five
factors: Positive Symptoms (Pos), Negative Symptoms (Neg),
Disorganised (Dis), Excited (Exc) and Negative Emotion Depressed
(Emd) (Cella et al., 2014a; Wallwork et al., 2012).
2.7. Autonomic system
The measurement of the autonomic activation was conducted using
a wearable device worn on the participant's wrist (i.e. Empatica E4)
(Garbarino et al., 2014). The device has 3 sensors recording: i) Electro-
dermal Activity (EDA) via skin conductivity (this assesses overall respon-
siveness to external events by assessing sympathetic nervous system
arousal); ii) Blood volume pulse with a photoplethysmography sensor.
From this measure it is possible to extract time between heart beat
peaks (inter-beat intervals IBI). From IBI data it is possible to extract
hear rate variability (HRV); inter-beat intervals (RR); standard devia-
tion of RR intervals (SDNN) and square root of themean squared differ-
ences of successive RR intervals (RMSSD); iii) Acceleration (ACC) via a 3-
axis accelerometer. Data from this sensor can be used to calculate activ-
ity levels.
2.8. Procedure
For the clinical group eligible participantswhowere considered suit-
able by their care teamwere approached and offered to take part in the
study. Upon entering the study demographic and clinical information
were collected from clinical records and during the initial assessment
appointment all the study assessment measures were administered.
Participates in the control group were screened for current and pastdetect the autonomic signature of illness severity in schizophrenia,
Table 1
Shows the mean (SD) of the demographic and clinical characteristics of people with
schizophrenia (SCZ) and healthy controls (HC).
SCZ M [SD] HC M [SD] Χ2 or t
Gender 18 M/10 F 13 M/12 F Χ2 = 0.8 n.s.
Age (years) 37.5 [10.8] 35.9 [12.5] t= 0.5 n.s.
Illness Lenght (Yrs) 11.8 [4.1]
PANSS5 Pos 9.8 [3.8] –
PANSS5 Neg 12.7 [5.8] –
PANSS5 Dis 7.7 [1.8] –
PANSS5 Exc 6.0 [2.6] –
PANSS5 Dep 9.9 [3.5] –
CPZ (mg) 367 [337] –
Structured Activity (hrs) 36 [21] 108 [39] t= 8.6***
*p b 0.05; **p b 0.01; ***p b 0.001.
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Interview (MINI) (Sheehan et al., 1998). All participants were briefed
on the use of the mHealth device and asked to wear it as much as pos-
sible for the following 6 days for themoment theywake up in themorn-
ing until bed time in the evening. Participants were asked to remove the
mHealth device in case this could become wet (e.g. showering, swim-
ming). Participants were contacted by phone twice during the assess-
ment period by a study researcher for troubleshooting. Information
collected by the wearable device was stored on the device memory
and downloaded on the study server during face-to-face meetings.
After the sixth day participants returned the device and completed the
acceptability measures.
2.9. Data pre-processing
Participants returned recording segments of different length.We ini-
tially decided to exclude short recordings (i.e. b60 min) as some HRV
parameters (e.g. SDNN) may be less informative over a shorter record-
ing period. Further we opted to consider only longer recordings as
these were considered more likely to include a different range of activ-
ities. After preliminary inspection we noticed that all participants had
several continuous recording exceeding 8 h. We therefore decided to
use only samples that had at least this length. All participants had at
least two 8-h samples. During the six days in which they were asked
to wear the device participants with schizophrenia completed on aver-
age 3.7 (SD1.3) - samples while controls 3.8 (SD1.2).
The EDA sensor collected data at a frequency of 4 Hz while the ACC
sensor sampled at 32 Hz. The IBI sensor returned the time between
heartbeat peaks. EDA datawas handled using Ledalab forMATLAB to re-
move artefacts (Benedek and Kaernbach, 2010). Mean EDA amplitude
was calculated for each sample. Heart rate variability parameters were
calculated using IBI values from the Empatica Algorithm 1 and 2 (see
Garbarino et al., 2014). Data was further processed with Kubios HRV
(Tarvainen et al., 2014) to extract standard deviation of all normal RR in-
tervals (SDNN) and rootmean square of the successive differences of RR
intervals (RMSSD) (Sollers et al., 2007).
From the ACC sensor we extracted an index of overall movement by
means of standard Euclideanmetric. This was computed for each of the
3-axis sensor at each sampling point and summed for the total record-
ing sample length, thus producing an indicator of overall extent of
movement during the recording period.
2.10. Data analysis
Data analysis was divided into three stages. Firstly the relationship
between physiological variables was examined with Spearman rho cor-
relation coefficient to assess the reliability of the parameter extracted.
Secondly, we examined between group differences with a set of t-tests
and univariate ANOVAs. Before this analysis we assessed distribution
normality using the Shapiro–Wilk test. We follow-up any significant
findingswith a post-hoc analysis controlling for age, time spent in struc-
tured activities (from the time-use survey) and activity levels (as re-
corded by the accelerometer sensor). Finally, we assessed the
relationship between the clinical and functional measures and physio-
logical variables using Spearman rank correlations. For this analysis
we controlled for multiple correlation and adjusted the significance
threshold to a more conservative p= 0.008 (Benjamini and Hochberg,
1995). For all other analysis the significant thresholdwas set at p b 0.05.
3. Results
Table 1 shows the demographic characteristics for the two groups
and the clinical characteristics for people with schizophrenia. The only
significant difference was in the amount of time spent in structured
activities.Please cite this article as: Cella, M., et al., Using wearable technology to
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All participants were able to use the watch according to the instruc-
tions received and completed the device acceptability questionnaire.
The result showed very similar acceptability scores between the two
groups. When asked about the acceptability of the research procedures
and the mHealth device use, people with schizophrenia endorsed at
least a good or excellent rating 81% of the times across all the items
while controls endorsed the same ratings 80% of the times.
3.2. Physiological data validity
We calculated correlations between the physiological variables to
assess validity. As expected HRV parameters showed strong and signif-
icant inter-correlations: mean RR correlated with SDNN (rho = 0.55;
p b 0.001) and with RMSSD (rho= 0.47; p b 0.001), SDNNwas corre-
lated with RMSSD (rho = 0.77; p b 0.001). Total movement levels
were positively correlated with EDA (rho = 0.47; p = 0.002) and
RR RMSSD (rho = 0.29; p = 0.037).
3.3. Group differences
Kolmogorov-Smirnov test revealed that EDA and ACC values were
non-normally distributed. For these variables we repeated the analyses
using non-parametric tests. There were no group differenced in EDA
(Mann-Whitney U = 126.0, n.s., see Fig. 1). Significant differences
were found for SDNN (F(1,52) = 6.4, p = 0.015; SCZ: 102 ± 34 vs.
HC:129 ± 44) and RMSSD (F(1,52) = 7.7, p= 0.008; SCZ: 70 ± 25 vs.
HC: 90 ± 27) and a trend toward significance for mean RR, F(1,52) =
4.5, p = 0.07; SCZ: 771 ± 121 vs. HC: 839 ± 147 (see Fig. 1). In all
these measures, participants with schizophrenia had lower values.
Group comparison on ACC data showed that people with schizophrenia
had overall lower movement levels than controls, F(1,52) = 5.3 p =
0.02. As ACC data were skewed we replicated this result using non-
parametric statistics (Mann-Whitney U = 470.5 p = 0.03).
Participants in the controls group had more hours of structured ac-
tivity compared with people with schizophrenia, F(1,52) = 74.4, p b
0.001; SCZ: 36 ± 21 vs. HC: 108±39. This result was confirmed with
non-parametric testing (Mann-Whitney U = 684, p b 0.001). We re-
peated all the analysis on physiological measures controlling for age,
time-use structured activity and movement. The only significant differ-
ence still observed was in RR RMSSD, F(1,49) = 4,6; p= 0.04.
3.4. Correlations with clinical/functional measures
In people with schizophrenia RR SDNN negatively correlated with
Positive symptoms (rho =−0.50, p= 0.007) while movement nega-
tively correlated with Negative symptoms (rho =−0.51, p= 0.006).
Number of weekly hours of structures activity correlatedwithmovement
levels (rho = 0.43, p = 0.02) and negatively with mean RR (rho =detect the autonomic signature of illness severity in schizophrenia,
Fig. 1.Mean values of EDA (μS), RR (ms), SDNN (ms) and RMSSD (ms) for people with schizophrenia (SCZ) and healthy controls (HC). Error bars represent standard deviations.
4 M. Cella et al. / Schizophrenia Research xxx (2017) xxx–xxx−0.50, p = 0.007). We did not find association between medication
and any of the autonomic parameters measured.
4. Discussion
In this study we evaluated the acceptability and feasibility of a new
mHealthmethod assessing autonomic activity in everyday life in people
with schizophrenia. We also compared measures of sympathetic and
parasympathetic activity collected with this method from people's ev-
eryday life between peoplewith schizophrenia and healthy controls. Fi-
nally we assessed the association between autonomic abnormalities,
functional difficulties and symptoms of schizophrenia.
Our data on acceptability and feasibility suggest that this is a viable
methodology for clinical studies. Evaluating these parameters is a nec-
essary and important first step when testing new methodologies.
mHealth devices present clinicians and researchers with an unprece-
dented opportunity to assess physiological parameters in real time
andwithout interferingwith people's lives. Thismay be particularly im-
portant for studies aiming to understand barriers to recovery in people
with psychosis as autonomic deregulation has been found to be associ-
ated with different illness chronicity features (e.g. Bar et al., 2008;
Chung et al., 2013; Kim et al., 2004; Valkonen-Korhonen et al., 2003).
In line with previous research our findings shows that people with
schizophrenia have autonomic abnormalities, in particular reduced
HRV (Bar et al., 2007; Iwamoto et al., 2012; Kim et al., 2004). Previous
research suggests that HRV reduction may be associated with reducedPlease cite this article as: Cella, M., et al., Using wearable technology to
Schizophr. Res. (2017), https://doi.org/10.1016/j.schres.2017.09.028functioning (Fujibayashi et al., 2009; Valkonen-Korhonen et al., 2003).
A number of hypotheses have been advanced on the role of autonomic
deregulations and functioning in people with schizophrenia. Our find-
ings suggest, in line with Montaquila et al., that autonomic abnormali-
ties are mostly relevant for the parasympathetic branch of the
autonomic system (Montaquila et al., 2015). This suggests that people
with schizophrenia may have adequate reactivity to arousing stimuli
but the parasympathetic system may fail to down-regulate this activa-
tion following habituation or stimulus removal. This study did not find
abnormal EDA values in the clinical group and this may be dependent
on the length of the recording period used (i.e. 8 h). Most of the studies
showing abnormal sympathetic activity in people with schizophrenia
use experimental designs evaluating event related activation on a
much shorter timescale (e.g. Castro et al., 2008).
Lower parasympathetic activity in the group of people with schizo-
phrenia was particularly evident for the standard deviation of RR inter-
vals after controlling for age, functioning and movements levels. This
index is considered more adequate for longer recordings as it measures
HRV cycles over prolonged time periods and is relatively independent
from activity levels therefore suggesting that HRV abnormalities may
be related to other illness features such as symptoms (Thayer et al.,
2012). This result did not entirely support the hypotheses that parasym-
pathetic abnormalities are linked to functioning difficulties (Khandoker
et al., 2010; Tarrier and Barrowclough, 1990; Toichi et al., 1999). How-
ever, it may be possible to reconcile these positions by considering
how fundamental to schizophrenia both parasympathetic deregulationdetect the autonomic signature of illness severity in schizophrenia,
5M. Cella et al. / Schizophrenia Research xxx (2017) xxx–xxxand functioning problems are. It is likely that relevant moderating and
mediating factors may intervene in modulating this relationship and
perhaps contributemore decisively to explain this relationship. Our cor-
relational analysis offers a potential candidate mediator for future
study: positive symptoms. Previous studies have also fund this symp-
tom cluster to be associatedwith autonomic deregulation and function-
ing problems (Kim et al., 2004). It is also possible that poor functioning
may be more influenced by other psychosocial aspects associated with
psychoses such as limited opportunities and social contact, poor of
self-esteem, social anxiety and low mood (Achim et al., 2011; Cella et
al., 2014b; Saarni et al., 2010). The causal pathway to reduced HRV in
psychosis remains uncertain and it is unclear if reduced HRV is the
cause or the consequence of poor functioning.
This study has limitations. We did not exclude participants on the
basis of their medication intake. It has been suggested in the literature
that some drugs (e.g. anticholinergic medications) may have an effect
on the parasympathetic systems (Agelink et al., 2001; Kim et al., 2013;
Rechlin et al., 1994). However these studies have not been replicated
and poorly adapt to the reality of clinical services where polypharmacy
is common. We recorded chlorpromazine equivalent levels and con-
trolled for it in the analysis; howeverwe did not findmedication having
a significant influence on any of the physiological parameters recorded.
A recentmeta-analysis by Alvares et al. (2016) supports our finding and
suggests that the impact of antipsychotic medication on HRV in people
with schizophrenia is small and largely non-significant. Two of our par-
ticipants in the clinical group were also prescribed with an antidepres-
sant medication. Future studies should consider more systematically
the role of depression and antidepressants as this may influence HRV
(Brunoni et al., 2013). Aside of medication tobacco use should also be
considered in future investigations as this may have an effect on the au-
tonomic system. We did not record people's activity levels using self-
assessed method (e.g. diary) as we wanted to record autonomic func-
tion without interfering with people's everyday life. As a result many
participants reported that they were “forgetting” they were wearing a
device. This is a positive aspect when considering future possible rou-
tine use of wearable devices however this meant that we were not
able tomonitor precisely people's activities. In the future studies should
consider using, alongsidewearable devices, Experience SamplingMeth-
odology (ESM) (Nelson et al., 2017). This method has now been used
extensively in people with psychosis (Edwards et al., 2016). Using
ESM in combination with mobile autonomic monitoring will link more
clearly how changes in mental health states affect people's autonomic
system and give us the opportunity to devise precise and truly person-
alized monitoring systems.
The more routine use of mHealth device in people with psychosis
may have important benefits. Several reports suggest that physical
health is poor in people with psychosis (Stubbs et al., 2016;
Vancampfort et al., 2015). Routine assessment of behavioural and phys-
iological parameters such as activity levels and HRV could provide key
information on people's wellbeing. Future interventions should capital-
ize on the possibility of tracking physiological parameters andmonitor-
ing these changes regularly.Contributors
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